{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:58:59Z","timestamp":1793761139720,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T00:00:00Z","timestamp":1684022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T00:00:00Z","timestamp":1684022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>No study has assessed the effects of the incorporation of isolated lidocaine into botulinum toxin for reducing its pain or complications. Studies on the dilution of botulinum toxin with other materials are as well extremely few, small, and limited methodologically. Therefore, we aimed to evaluate, for the first time, the effects of the incorporation of lidocaine alone into botulinum toxin type\u00a0A on post-injection pain and complications. In this 2-week prospective, multicenter, double-blind randomized placebo-controlled clinical trial, 729 participants (667 females) were enrolled. They were randomized into placebo and lidocaine dilutions (about 2:1), and then into two brands of toxins (Dysport versus Xeomin). Hence, there were 4 subgroups. In the 2 experimental subgroups, botulinum toxin was diluted with 2% lidocaine without adrenaline; in the 2 control subgroups, botulinum toxin was diluted with normal saline as a placebo. After injection, the pain level was recorded (as an 11-scale numerical rating scale from 0 to 10). After 2 weeks, post-injection complications were assessed based on the participants\u2019 reports and the surgeon\u2019s observations. Data were analyzed using 3-way ANCOVA, multiple binary logistic regression, and bivariable analyses (\u03b1\u2009=\u20090.05, \u03b2\u2009\u2264\u20090.1). The mean\u2009\u00b1\u2009SD pain levels in the lidocaine group (n\u2009=\u2009263) and the placebo group (n\u2009=\u2009466) were 3.51\u2009\u00b1\u20092.04 and 4.15\u2009\u00b1\u20092.35, respectively. The mean\u2009\u00b1\u2009SD pain levels in the subgroups \u2018Xeomin-Lidocaine (n\u2009=\u200961), Dysport-Lidocaine (n\u2009=\u2009202), Xeomin-Placebo (n\u2009=\u2009133), and Dysport-Placebo (n\u2009=\u2009333)\u2019 were respectively 3.39\u2009\u00b1\u20091.86, 3.55\u2009\u00b1\u20092.09, 4.61\u2009\u00b1\u20092.49, and 3.97\u2009\u00b1\u20092.24. Lidocaine incorporation (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), Dysport brand (<jats:italic>P<\/jats:italic>\u2009=\u20090.030), and younger age (<jats:italic>P<\/jats:italic>\u2009=\u20090.032) [but not sex (<jats:italic>P<\/jats:italic>\u2009=\u20090.406)] reduced pain. The only significant findings for 2-week complications were for the associations observed between aging with increased asymmetry (<jats:italic>P<\/jats:italic>\u2009=\u20090.022, OR\u2009=\u20091.032) and a need for a retouch (<jats:italic>P<\/jats:italic>\u2009=\u20090.039, OR\u2009=\u20091.021). Botulinum toxin dilution with lidocaine alone (without adrenaline or other ingredients) can reduce pain without affecting postinjection complications. Toxin brands may cause different extents of pain. Aging, but not sex, may increase pain. Two-week complications were not affected by any factors, except aging in the case of asymmetry and the need for a botulinum toxin retouch.\n<\/jats:p>","DOI":"10.1038\/s41598-023-34973-4","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T12:12:21Z","timestamp":1684152741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of lidocaine incorporation (without epinephrine) on pain and 2-week complications of botulinum toxin: a double-blind randomized placebo-controlled clinical trial"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-5625","authenticated-orcid":false,"given":"Farzin","family":"Sarkarat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-8751","authenticated-orcid":false,"given":"Diba","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-5756","authenticated-orcid":false,"given":"Roozbeh","family":"Kahali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-0632","authenticated-orcid":false,"given":"Ali","family":"Fateh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-3133","authenticated-orcid":false,"given":"Vahid","family":"Rakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,14]]},"reference":[{"issue":"1\u20132","key":"34973_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","volume":"109","author":"A Burgen","year":"1949","unstructured":"Burgen, A., Dickens, F. & Zatman, L. The action of botulinum toxin on the neuro-muscular junction. J. Physiol. 109(1\u20132), 10\u201324 (1949).","journal-title":"J. Physiol."},{"key":"34973_CR2","first-page":"223","volume-title":"Botulinum Toxin for Axillary Hyperhidrosis","author":"C Prati","year":"2020","unstructured":"Prati, C. & Peruzzo, J. Botulinum Toxin for Axillary Hyperhidrosis 223\u2013227 (Springer, 2020)."},{"key":"34973_CR3","unstructured":"Kim A, Jung J, Pak A. Botulinum toxin type A reconstituted in lidocaine with epinephrine for facial rejuvenation: results of a participant satisfaction survey. Cutis, Suppl, 13-8 (2013)."},{"issue":"3","key":"34973_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.17245\/jdapm.2016.16.3.151","volume":"16","author":"K-S Park","year":"2016","unstructured":"Park, K.-S., Lee, C.-H. & Lee, J.-W. Use of a botulinum toxin A in dentistry and oral and maxillofacial surgery. J. Dent. Anesth. Pain med. 16(3), 151\u2013157 (2016).","journal-title":"J. Dent. Anesth. Pain med."},{"issue":"2","key":"34973_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/0975-5950.183860","volume":"6","author":"S Srivastava","year":"2015","unstructured":"Srivastava, S., Kharbanda, S., Pal, U. & Shah, V. Applications of botulinum toxin in dentistry: A comprehensive review. Natl. J. Maxillofac. Surg. 6(2), 152 (2015).","journal-title":"Natl. J. Maxillofac. Surg."},{"issue":"7","key":"34973_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"M Brin","year":"1999","unstructured":"Brin, M. et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A\u2013resistant cervical dystonia. Neurology 53(7), 1431 (1999).","journal-title":"Neurology"},{"issue":"19","key":"34973_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","volume":"70","author":"M Naumann","year":"2008","unstructured":"Naumann, M. et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19), 1707\u20131714 (2008).","journal-title":"Neurology"},{"issue":"7","key":"34973_CR8","doi-asserted-by":"publisher","first-page":"e027953","DOI":"10.1136\/bmjopen-2018-027953","volume":"9","author":"CP Herd","year":"2019","unstructured":"Herd, C. P. et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open 9(7), e027953 (2019).","journal-title":"BMJ Open"},{"issue":"1","key":"34973_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/10408410590912952","volume":"31","author":"H Shukla","year":"2005","unstructured":"Shukla, H. & Sharma, S. Clostridium botulinum: A bug with beauty and weapon. Crit. Rev. Microbiol. 31(1), 11\u201318 (2005).","journal-title":"Crit. Rev. Microbiol."},{"issue":"4","key":"34973_CR10","first-page":"212","volume":"22","author":"M Flanders","year":"1987","unstructured":"Flanders, M. et al. Injection of type A botulinum toxin into extraocular muscles for correction of strabismus. Can. J. Ophthalmol. J. Can. D\u2019ophtalmol. 22(4), 212\u2013217 (1987).","journal-title":"Can. J. Ophthalmol. J. Can. D'ophtalmol."},{"issue":"2","key":"34973_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00006534-198908000-00027","volume":"84","author":"RP Clark","year":"1989","unstructured":"Clark, R. P. & Berris, C. E. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast. Reconstr. Surg. 84(2), 353\u2013355 (1989).","journal-title":"Plast. Reconstr. Surg."},{"key":"34973_CR12","volume-title":"Botulinum Toxin in Facial Rejuvenation","author":"K Coleman","year":"2019","unstructured":"Coleman, K. Botulinum Toxin in Facial Rejuvenation (Elsevier, 2019)."},{"issue":"2","key":"34973_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/IOP.0b013e3181b8dc0b","volume":"26","author":"ZY Williams","year":"2010","unstructured":"Williams, Z. Y., Oester, A. E. Jr., Stinnett, S., Morris, C. & Woodward, J. A. Cosmetic surgery survey of American Society of Oculoplastic and Reconstructive Surgery members and a 6-year comparison. Ophthalmic Plast. Reconstr. Surg. 26(2), 95\u201399 (2010).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"1","key":"34973_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","volume":"18","author":"JD Carruthers","year":"1992","unstructured":"Carruthers, J. D. & Carruthers, J. A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J. Dermatol. Surg. Oncol. 18(1), 17\u201321 (1992).","journal-title":"J. Dermatol. Surg. Oncol."},{"issue":"7","key":"34973_CR15","doi-asserted-by":"publisher","first-page":"1190 e1","DOI":"10.1016\/j.joms.2020.02.016","volume":"78","author":"KC Lee","year":"2020","unstructured":"Lee, K. C., Pascal, A. B., Halepas, S. & Koch, A. What are the most commonly reported complications with cosmetic botulinum toxin type A treatments?. J. Oral Maxillofac. Surg. 78(7), 1190 e1-e9. https:\/\/doi.org\/10.1016\/j.joms.2020.02.016 (2020).","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"12","key":"34973_CR16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1055\/s-0029-1246237","volume":"88","author":"F Haubner","year":"2009","unstructured":"Haubner, F. Simultaneous injection of lidocaine improves predictability of effect of botulinum toxin. Laryngo-Rhino-Otologie 88(12), 764 (2009).","journal-title":"Laryngo-Rhino-Otologie"},{"issue":"4","key":"34973_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00006534-199204000-00001","volume":"89","author":"TP Whetzel","year":"1992","unstructured":"Whetzel, T. P. & Mathes, S. J. Arterial anatomy of the face: An analysis of vascular territories and perforating cutaneous vessels. Plast. Reconstr. Surg. 89(4), 591\u2013603 (1992).","journal-title":"Plast. Reconstr. Surg."},{"issue":"7","key":"34973_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4065\/75.7.701","volume":"75","author":"HG Gassner","year":"2000","unstructured":"Gassner, H. G. & Sherris, D. A. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: A randomized controlled study. Mayo Clin. Proc. 75(7), 701\u2013704. https:\/\/doi.org\/10.4065\/75.7.701 (2000).","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"34973_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","volume":"304","author":"M Kerscher","year":"2012","unstructured":"Kerscher, M., Roll, S., Becker, A. & Wigger-Alberti, W. Comparison of the spread of three botulinum toxin type A preparations. Arch. Dermatol. Res. 304(2), 155\u2013161 (2012).","journal-title":"Arch. Dermatol. Res."},{"issue":"2","key":"34973_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.toxicon.2011.05.012","volume":"58","author":"HF Stone","year":"2011","unstructured":"Stone, H. F., Zhu, Z., Thach, T. Q. & Ruegg, C. L. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon 58(2), 159\u2013167 (2011).","journal-title":"Toxicon"},{"issue":"2","key":"34973_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2044.2006.04901.x","volume":"62","author":"DJ Newton","year":"2007","unstructured":"Newton, D. J., McLeod, G. A., Khan, F. & Belch, J. J. Mechanisms influencing the vasoactive effects of lidocaine in human skin. Anaesthesia 62(2), 146\u2013150. https:\/\/doi.org\/10.1111\/j.1365-2044.2006.04901.x (2007).","journal-title":"Anaesthesia"},{"issue":"1","key":"34973_CR22","doi-asserted-by":"publisher","first-page":"e15444","DOI":"10.5812\/aapm.15444","volume":"4","author":"SE Golzari","year":"2014","unstructured":"Golzari, S. E., Soleimanpour, H., Mahmoodpoor, A., Safari, S. & Ala, A. Lidocaine and pain management in the emergency department: A review article. Anesth. Pain Med. 4(1), e15444. https:\/\/doi.org\/10.5812\/aapm.15444 (2014).","journal-title":"Anesth. Pain Med."},{"key":"34973_CR23","volume-title":"Botulinum Toxin for Facial Harmony","author":"A Fl\u00e1vio","year":"2018","unstructured":"Fl\u00e1vio, A. Botulinum Toxin for Facial Harmony (Quintessence Publishing, 2018)."},{"key":"34973_CR24","unstructured":"Bove PR, Raffaele. Botulinum Toxin Type A reconstituted with lidocaine. J. Adv. Plast. Surg. Res. (2015)."},{"key":"34973_CR25","first-page":"152","volume":"107","author":"M de Quadros","year":"2017","unstructured":"de Quadros, M., Webber, A., Ferreira, M. S. & Schwarzbach, A. P. Randomized study comparing onabotulinum toxin diluted in lidocaine and epinephrine versus saline solution for the treatment of periocular lines. Surg. Cosmet. Dermatol. 107, 152\u2013155 (2017).","journal-title":"Surg. Cosmet. Dermatol."},{"key":"34973_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31907\/2414-2093.2015.01.1","volume":"1","author":"R Ravso","year":"2015","unstructured":"Ravso, R. & Bove, P. Botulinum toxin type A reconstituted with lidocaine. J. Adv. Plast. Surg. Res. 1, 1\u20134 (2015).","journal-title":"J. Adv. Plast. Surg. Res."},{"issue":"10","key":"34973_CR27","first-page":"1148","volume":"10","author":"MS Nestor","year":"2011","unstructured":"Nestor, M. S. & Ablon, G. R. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis activity measurement standard. J. Drugs Dermatol. 10(10), 1148\u20131157 (2011).","journal-title":"J. Drugs Dermatol."},{"issue":"2","key":"34973_CR28","doi-asserted-by":"publisher","first-page":"e3417","DOI":"10.1097\/GOX.0000000000003417","volume":"9","author":"GS Jung","year":"2021","unstructured":"Jung, G. S. & Kim, H. S. A novel technique to reduce pain from intradermal injection of botulinum toxin type A. Plast. Reconstr. Surg. Glob. Open 9(2), e3417. https:\/\/doi.org\/10.1097\/GOX.0000000000003417 (2021).","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"34973_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/ccid.s155023","volume":"11","author":"A Alsantali","year":"2018","unstructured":"Alsantali, A. A comparative trial of ice application versus EMLA cream in alleviation of pain during botulinum toxin injections for palmar hyperhidrosis. Clin. Cosmet. Investig. Dermatol. 11, 137\u2013140. https:\/\/doi.org\/10.2147\/ccid.s155023 (2018).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"1","key":"34973_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaad.2019.09.088","volume":"83","author":"A Vent","year":"2020","unstructured":"Vent, A. et al. Buffered lidocaine 1%\/epinephrine 1:100,000 with sodium bicarbonate (sodium hydrogen carbonate) in a 3:1 ratio is less painful than a 9:1 ratio: A double-blind, randomized, placebo-controlled, crossover trial. J. Am. Acad. Dermatol. 83(1), 159\u2013165. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.088 (2020).","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34973-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34973-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34973-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T12:12:28Z","timestamp":1684152748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34973-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34973"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34973-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,14]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7812"}}